

# **Notice of Allowability**

**Application No.**

10/072,722

**Examiner**

Padmavathi v Baskar

**Applicant(s)**

TSANG ET AL.

**Art Unit**

1645

## **-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--**

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to 12/29/03 and 3/15/04.
2. ☒ The allowed claim(s) is/are 1-7 and 21-27 and have been renumbered as 1-13 respectively.
3. ☐ The drawings filed on \_\_\_\_\_ are accepted by the Examiner.
4. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a) ☐ All b) ☐ Some\* c) ☐ None of the:
    1. ☐ Certified copies of the priority documents have been received.
    2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

5. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
  - (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
    - 1) ☐ hereto or 2) ☐ to Paper No./Mail Date \_\_\_\_\_.
  - (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

## **Attachment(s)**

1. ☐ Notice of References Cited (PTO-892)
2. ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3. ☐ Information Disclosure Statements (PTO-1449 or PTO/SB/08), Paper No./Mail Date \_\_\_\_\_
4. ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material
5. ☐ Notice of Informal Patent Application (PTO-152)
6. ☒ Interview Summary (PTO-413), Paper No./Mail Date 3/12/04.
7. ☒ Examiner's Amendment/Comment
8. ☐ Examiner's Statement of Reasons for Allowance
9. ☐ Other \_\_\_\_\_.

#### **DETAILED ACTION**

1. Applicant's after final amendments filed on 12/29/03 and 3/15/04 are acknowledged.

#### ***Status of Claims***

2. Claim 1 has been amended.

Claim 2 is cancelled.

Claims 1-7 and 21-27 are pending in the application.

#### ***Rejections withdrawn***

3. In view of the amendment to the claim 1 and arguments of record, the rejections under 35 U.S.C. 102 (b) as being anticipated by McManus Donald 199 is withdrawn since the prior art does not disclose isolated adult Taenia Solium excretory/secretory polypeptide that has a molecular weight of approximately 33 kD, 38 kD or 42 kD as determined by SDS PAGE analysis.

4. In view of the amendment to the claim 1 and arguments of record, the rejections under 35 U.S.C. 102 (b) as being anticipated by under 35 U.S.C. 102(b) as being anticipated by Varma et al 1986 (Indian Journal of Animal Sciences 56 (6): 621-627) is withdrawn since the prior art does not disclose isolated, adult Taenia solium excretory/secretory polypeptide that has a molecular weight of approximately 33 kD, 38 kD or 42 kD as determined by SDS PAGE analysis.

5. The rejection of claims under 35 U.S.C. 103(a) as being unpatentable over McManus Donald or Varma et al 1986 in view of Zuk et al also withdrawn for the reasons set forth in Paragraphs # 3 and 4.

Art Unit: 1645

**Remarks**

6. The instant claims define novel isolated excretory and secretory polypeptides from adult worms that could be used to detect an adult *T. solium* infection from a larval infection in a sample using an immunoassay.

7. Therefore, Claims 1-7 and 21-27 are allowed and have been renumbered as 1-13 respectively.

**Conclusions**

8. Papers related to this application may be submitted to Group 1600, AU 1645 by facsimile transmission. Papers should be transmitted via the PTO Fax Center, which receives transmissions 24 hours a day and 7 days a week. The transmission of such papers by facsimile must conform to the notice published in the Official Gazette, 1096 OG 30, November 15, 1989. The RightFax number for submission of before-final amendments is (703) 872-9306. The RightFax number for submission of after-final amendments is (703) 872-9307.

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Padma Baskar Ph.D., whose telephone number is ((571) 272-0853. A message may be left on the Examiner's voice mail system. The Examiner can normally be reached on Monday to Friday from 6.30 a.m. to 4.00 p.m. except First Friday of each bi-week.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette Smith can be reached on (571) 272-0864. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (571) 272-1600.

Padma Baskar Ph.D.

3/17/04

  
MARK NAVARRO  
PRIMARY EXAMINER